KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
KIORA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.38−0.02 (-0.83%)
Close on Oct 19, 2026
- Market cap
- $14.70M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.33 (−12.18%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
KIORA PHARMACEUTICALS INC saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$8.61M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$12.83M
TTM Q2 2026
Free cash flow
-$8.61M
TTM Q2 2026
EPS, diluted
-$2.57
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $14.70M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.87
- Dividend yield
- –
- Free cash flow yield
- -58.59%
Fundamentals
- Revenue
- $0
- Net income
- -$10.99M
- EPS, diluted
- -$2.57
- Free cash flow
- -$8.61M
- Book value per share
- $2.73
- Diluted shares
- 6M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$12.83M
Net income
-$10.99M
EPS, diluted
-$2.57
Free cash flow
-$8.61M
Reported periodTrailing twelve months